Search
omacetaxine mepesuccinate; homoharringtonine (Synribo)
Indications:
- treatment of chronic myelogenous leukemia (CML) resistant to 2 or more tyrosine kinase inhibitors
Adverse effects:
- thrombocytopenia, anemia, neutropenia, lymphopenia
- diarrhea, nausea
- fatigue, asthenia
- injection site reaction
- pyrexia, infection
Mechanism of action:
- inhibits protein translation by preventing the initial elongation step of protein synthesis
- interacts with the ribosomal A-site & prevents correct positioning of amino acid side chains of incoming aminoacyl-tRNAs
- acts only on the initial step of protein translation
- does not inhibit protein synthesis from mRNAs that have already begun translation
General
antineoplastic agent (chemotherapeutic agent)
alkaloid
References
- Wikipedia: Omacetaxine mepesuccinate
http://en.wikipedia.org/wiki/Omacetaxine_mepesuccinate
- Wetzler M, Segal D
Omacetaxine as an anticancer therapeutic: what is old is new
again.
Curr Pharm Des. 2011;17(1):59-64.
PMID: 21294709